INS and type 1 diabetes mellitus: In the DEPICT trials (370), administration of 5 or 10 mg dapagliflozin along with insulin to overweight individuals with T1D for 52 weeks decreased HbA1c by 0.2 and 0.23%, body weight by 2.57 and 3.34 kg, and daily insulin dose by 8.3 and 10.51%, respectively.